Skip to main content
Press Release

Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.–(BUSINESS WIRE)–December 21, 2016–

Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, today announced that it will participate in the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. John Pedersen, Chief Executive Officer, is scheduled to present on Thursday, January 12, 2017 at 9:30 a.m. Pacific Time in the Elizabethan D room.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161221005471/en/

About Augmenix, Inc.

June 5th: The AI Audit in NYC

Join us next week in NYC to engage with top executive leaders, delving into strategies for auditing AI models to ensure fairness, optimal performance, and ethical compliance across diverse organizations. Secure your attendance for this exclusive invite-only event.

Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.

Augmenix
Eileen Gardner, RN, 781-902-1625
egardner@augmenix.com